BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 22946472)

  • 21. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient.
    Bonvalot S; Rimareix F; Causeret S; Le Péchoux C; Boulet B; Terrier P; Le Cesne A; Muret J
    Ann Surg Oncol; 2009 Dec; 16(12):3350-7. PubMed ID: 19830495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis.
    Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ
    Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
    Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
    J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.
    Grünhagen DJ; de Wilt JH; Verhoef C; van Geel AN; Eggermont AM
    Eur J Surg Oncol; 2005 Oct; 31(8):912-6. PubMed ID: 16098709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.
    Lans TE; Grünhagen DJ; de Wilt JH; van Geel AN; Eggermont AM
    Ann Surg Oncol; 2005 May; 12(5):406-11. PubMed ID: 15915375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
    Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
    J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Liénard D; Kroon BB; Schlag PM; Ben-Ari G; Lejeune FJ
    Semin Oncol; 1997 Oct; 24(5):547-55. PubMed ID: 9344321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas.
    Deroose JP; Grünhagen DJ; de Wilt JH; Eggermont AM; Verhoef C
    Eur J Cancer; 2015 Feb; 51(3):367-73. PubMed ID: 25529370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma.
    Nachmany I; Subhi A; Meller I; Gutman M; Lahat G; Merimsky O; Klausner JM
    Eur J Surg Oncol; 2009 Feb; 35(2):209-14. PubMed ID: 18295442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan.
    Lev-Chelouche D; Abu-Abeid S; Kollander Y; Meller I; Isakov J; Merimsky O; Klausner JM; Gutman M
    J Surg Oncol; 1999 Mar; 70(3):185-9. PubMed ID: 10102350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased shedding of soluble TNF-receptor 1 during hyperthermic TNF-α-based isolated limb perfusion.
    Grabellus F; Podleska LE; Bjerlestam S; Sheu SY; Lendemans S; Schmid KW; Taeger G
    Int J Hyperthermia; 2011; 27(1):33-41. PubMed ID: 21073296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
    Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
    J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
    Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature.
    Podleska LE; Funk K; Umutlu L; Grabellus F; Taeger G; de Groot H
    Br J Cancer; 2015 Aug; 113(4):645-52. PubMed ID: 26171939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
    Hoving S; Brunstein F; aan de Wiel-Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
    Cancer Res; 2005 May; 65(10):4300-8. PubMed ID: 15899822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?
    Bonvalot S; Laplanche A; Lejeune F; Stoeckle E; Le Péchoux C; Vanel D; Terrier P; Lumbroso J; Ricard M; Antoni G; Cavalcanti A; Robert C; Lassau N; Blay JY; Le Cesne A
    Ann Oncol; 2005 Jul; 16(7):1061-8. PubMed ID: 15930042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
    Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
    Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
    Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V
    In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncological outcome after hyperthermic isolated limb perfusion for primarily unresectable versus locally recurrent soft tissue sarcoma of extremities.
    Vassos N; Brunner M; Perrakis A; Göhl J; Grützmann R; Hohenberger W; Croner RS
    Surg Oncol; 2020 Dec; 35():162-168. PubMed ID: 32882523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.